Study of Continuous Glucose Monitoring After Gestational Diabetes Assessing Use and Patient Experience in Early Postpartum Women

What this Trial Is About

Gestational diabetes GDM affects many women during pregnancy and increases the risk of developing type 2 diabetes within three years after delivery. However, follow-up screening rates after pregnancy are low due to challenges with the recommended oral glucose tolerance test OGTT, which requires fasting and lengthy visits. This research aims to evaluate if using continuous glucose monitors CGM, small sensors placed under the skin, can improve postpartum diabetes screening and quality of life for women with recent GDM. In this study, 20 postpartum women with recent GDM will wear CGMs for up to 10 days at 6-8 weeks after giving birth. After wearing the CGM, participants will complete surveys about their experience and satisfaction. At 10-12 weeks postpartum, they will undergo the standard OGTT and be interviewed to compare their experiences with both screening methods. Additionally, at 11-14 months postpartum, a blood test will be done to check hemoglobin A1c for signs of insulin resistance. Participants will be involved in wearing the CGM device, completing surveys about their quality of life and glucose monitoring satisfaction, and attending follow-up visits for the OGTT and blood tests. Researchers will analyze blood glucose trends from the CGM and compare these with OGTT results to assess the accuracy and acceptability of CGM as a screening tool. The study will monitor participants for up to 15 weeks from enrollment, with a long-term follow-up blood test at about one year postpartum.

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot